The estimated Net Worth of Anthony L. Boral is at least $5.97 Milhão dollars as of 14 December 2020. Anthony Boral owns over 10,000 units of Blueprint Medicines Corp stock worth over $3,302,004 and over the last 9 years he sold BPMC stock worth over $27,856. In addition, he makes $2,637,200 as Chief Medical Officer at Blueprint Medicines Corp.
Anthony has made over 11 trades of the Blueprint Medicines Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of BPMC stock worth $150,100 on 14 December 2020.
The largest trade he's ever made was exercising 23,136 units of Blueprint Medicines Corp stock on 17 September 2020 worth over $264,907. On average, Anthony trades about 6,232 units every 79 days since 2016. As of 14 December 2020 he still owns at least 38,147 units of Blueprint Medicines Corp stock.
You can see the complete history of Anthony Boral stock trades at the bottom of the page.
Dr. Anthony L. Boral M.D., Ph.D. serves as Chief Medical Officer of the Company. He has served as our chief medical officer since January 2016 and previously served as our senior vice president, clinical development from February 2015 to December 2015. Prior to joining us, from November 2010 to February 2015, Dr. Boral worked at the Novartis Institutes for BioMedical Research, or Novartis, as executive director, oncology clinical research, serving as deputy site head for the Cambridge, Massachusetts site since 2013. At Novartis, Dr. Boral was responsible for the clinical aspects of various first-in-human compounds, including most recently ceritinib, an anaplastic lymphoma kinase inhibitor, and Novartis’ immune checkpoint inhibitor programs. Prior to Novartis, from 2002 to 2010 he worked at Millennium Pharmaceuticals, Inc., or Millennium, a biotechnology company in Cambridge, Massachusetts, which is now a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, or Takeda, including as vice president of oncology clinical research from October 2007 to October 2010. At Millennium, Dr. Boral was responsible for various aspects of the development of VELCADE®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkin’s lymphoma. Dr. Boral received a B.A. from Wesleyan University, and an M.D. and a Ph.D. from the Albert Einstein College of Medicine, in New York.
As the Chief Medical Officer of Blueprint Medicines Corp, the total compensation of Anthony Boral at Blueprint Medicines Corp is $2,637,200. There are 6 executives at Blueprint Medicines Corp getting paid more, with Jeffrey Albers having the highest compensation of $9,362,370.
Anthony Boral is 57, he's been the Chief Medical Officer of Blueprint Medicines Corp since 2016. There are 7 older and 21 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
Anthony's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr, eLonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: